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Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that has no effective
treatment. The lack of any specific biomarker that can help in the diagnosis or prognosis of ALS has
made the identification of biomarkers an urgent challenge. Multiple panels have shown alterations
in levels of numerous cytokines in ALS, supporting the contribution of neuroinflammation to the
progressive motor neuron loss. However, none of them is fully sensitive and specific enough to
become a universal biomarker for ALS. This review gathers the numerous circulating cytokines that
have been found dysregulated in both ALS animal models and patients. Particularly, it highlights
the opposing results found in the literature to date, and points out another potential application of
inflammatory cytokines as therapeutic targets.
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1. Introduction
Amyotrophic lateral sclerosis (ALS) is one of the most serious motor neuron diseases, and the most
common adult motor neuron disease. It is characterized by loss of the cortex, brainstem, and spinal
cord motor neurons (MNs), leading to muscle paralysis, and finally premature death due to respiratory
failure within 2–5 years after diagnosis. Unfortunately, to date, no effective therapies able to cure the
disease are available. More than 90% of ALS cases are sporadic with unknown causes. On the other
hand, around 10% of ALS patients have a family history, involving mutations in a number of genes,
such as Cu2+/Zn2+ superoxide dismutase 1 (SOD1), TAR DNA binding protein 43 (TDP-43), fused in
sarcoma (FUS) and chromosome 9 open reading frame 72 (C9ORF72) repeat expansions [1]. These
mutations found in ALS have allowed the development of animal models that are helpful in the study
of this disease. One of the best characterized animal models for ALS is the SOD1G93A mouse model,
which carries a G93A mutation (substitution of Glycine to Alanine at codon 93) in the human SOD1
gene, and presents both clinical and pathological characteristics of ALS patients [2].
The diagnosis of ALS is based on clinical tests and electrophysiological studies [3]. However,
there is not a definitive diagnostic test for ALS, and the difficulty to reach it leads to the delay of
diagnosis up to one year after the onset of symptoms. In addition, although the ALS Functional Rating
Scale–Revised (ALSFRS-R) can functionally measure ALS progression [4], the prognosis in each patient
still remains uncertain and challenging to anticipate.
Numerous mechanisms have been proposed to explain the degeneration of motor neurons,
including misfolded protein aggregation and impaired degradation, glutamate excitotoxicity, increased
oxidative stress, neuroinflammation and mitochondrial dysfunction [5]. However, the cause of motor
neuron degeneration in ALS is still unclear.
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2. The Necessity of Identifying Biomarkers for ALS
There is an imperious need to identify biomarkers that can help diagnose the disease at earlier stages
and also to predict the course of the disease that allow following of more accurate therapeutic strategies.
The ideal biomarker should be sensitive enough to diagnose ALS at the pre-symptomatic stage; specific
for ALS and able to discriminate from other clinically similar neurodegenerative diseases; able to predict
the progression of the disease in each patient; and easily accessible and applicable for all patients, despite
their physical condition [6]. Although the origin of ALS remains unknown, multiple panels of biomarkers
have been described in ALS patients and murine models to explain the progressive motor neuron loss
and muscle atrophy, including imaging, electrophysiological and wet biomarkers [7].
Neuroimaging biomarkers allow a faithful visualization of the structural alterations happening in
the tissue of study when comparing them with healthy tissues. Different brain imaging techniques
have been used to detect these pathological changes in ALS patients, such as magnetic resonance
imaging (MRI), magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI) and positron
emission tomography (PET) [8,9]. As a result of using these techniques, some pathological alterations
regarding cortical atrophy, neuronal integrity and brain white matter abnormalities have been positively
correlated with progression of the disease or resulted helpful in the diagnosis [10–13]. Although some
promising imaging biomarkers have been found, none of them is fully sensitive and specific enough
for ALS diagnosis or prognosis.
Numerous neurophysiologic biomarkers have been identified and proposed as biomarkers that
help in the early diagnosis and monitoring of the progression of the disease [14]. Transcranial magnetic
stimulation (TMS) technique can detect cortical hyperexcitability at early stages of the disease, which
has been correlated with upper motor neuron dysfunction [15]. On the other hand, the course of ALS
can be monitored by assessing lower motor neuron dysfunction using electrical impedance myography,
axonal excitability testing, the motor unit number index and muscle ultrasonography [15–17]. However,
despite the potential neurophysiological biomarkers found so far in assessing progression and early
diagnosis, further studies should be conducted involving larger ALS cohorts [15].
Multiple molecular markers have been described in cerebrospinal fluid (CSF), plasma, serum,
and even urine and saliva. Unlike CSF, the other fluids possess the advantage of being easily accessible
and do not require invasive methods to obtain them, which is an important feature of the ideal
biomarker. For this reason, over the last decades, several studies have been conducted to discover
new biomarkers in biofluids that are derived from different pathological mechanisms of ALS [18–22].
The best considered biomarkers candidates are inflammatory molecules, metabolic markers and
neurofilaments (NFs) [23,24].
To date, NFs are the most promising biomarkers for ALS. Particularly, both NF heavy chain (NFH)
and NF light chain (NFL) levels measured in CSF and blood samples can be used to differentiate
ALS patients from healthy subjects and/or other neurological diseases [25]. Furthermore, NFH and
NFL levels in CSF were negatively correlated with disease duration, which address NFs as potential
biomarkers for both diagnosis and prognosis of ALS [25].
Regarding inflammatory mediators, large panels of cytokines, including numerous interleukins,
and immune cells, such as T regulatory cells (Treg), have been identified in CSF, plasma or serum,
and have been correlated with faster or slower progression [26–28]. Cytokines and other inflammatory
proteins will be discussed in depth in the following sections.
The study of metabolic alterations in ALS patients is an increasing field of knowledge and more
studies are needed to identify more reliable biomarkers related to metabolic changes in different
tissues, such as CSF, blood and muscle [29,30]. For example, findings about glutamate levels in CSF
as a metabolic biomarker of disease progression in patients remain controversial [19]. Nevertheless,
in plasma samples, glutamate levels were increased and correlated with the disease duration and with
patients that exhibited spinal onset [31,32]. In addition, glutamate levels can be used as a metabolic
biomarker in serum in response to drug intervention [33]. On the other hand, mass spectrometry
has allowed the identification of different metabolic profiles where several amino acids have shown
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different levels in blood and CSF of ALS patients compared to their controls; these metabolites include
argine, lysine, serine and leucine, among others [19]. Other metabolites to consider are creatine and
creatinine, which have been found dysregulated in CSF and blood [19,32], and used as molecular
targets in a clinical trial [34]. Although altered metabolic profiles have been described in plasma
samples of ALS patients, more reliable biomarkers that can contribute to disease progression and
survival need to be identified [19].
microRNAs (miRNAs) are other potential biomarkers mainly due to their remarkably stability
in body fluids. They have been found altered in CSF, plasma and serum from ALS patients and the
SOD1G93A mouse model, such as MIR206, MIR143-3p, MIR338-3p [35–38]. Although some of these
miRNAs are not specific for ALS, such as MIR206, it has been suggested that their combination could
form part of a more integrative approach to help with ALS diagnosis and prognosis [38].
In urine, only one biomarker with prognostic value for ALS has been described, the extracellular
domain of p75 neurotrophin receptor (p75ECD), whose levels showed an association with disease
progression [39].
In spite of the fact that numerous potential biomarkers have been identified so far, none of them
separately has sufficient sensitivity or specificity to become a universal biomarker for ALS. The lack of
a robust biomarker is also reflected by some contradictory results and inconsistencies found in the
literature, possibly due to patient heterogeneity and the complex scenario comprising this disease.
3. The Role of The Immune System in ALS
The dysregulation of the immune system in ALS results in increased central and peripheral
inflammatory responses [40]. Neuroinflammation is characterized by microglial activation, astrogliosis,
infiltration of T lymphocytes and monocytes, and overproduction of inflammatory cytokines [41–43].
Both innate and adaptive immune responses are involved in ALS progression and can promote
either neuroprotection or neurotoxicity depending on disease stage, evidencing a dual role of
inflammation in ALS [44]. Initially, there is an early anti-inflammatory or neuroprotective phase,
where neurotrophic factors and anti-inflammatory cytokines, such as interleukin (IL)-4 and IL-10,
are secreted by surrounding astrocytes and M2 microglia. As the disease progresses, the neuroprotective
response changes to a cytotoxic phase due to the activation of M1 microglia and the consequent release
of toxic factors, including reactive oxygen species (ROS) and pro-inflammatory cytokines, such as
IL-1β and tumor necrosis factor (TNF)-α, which causes progressive injury to the MN [45].
Apart from microglia and astrocytes, T lymphocytes of the adaptive immune response also play a
relevant role in the neurodegeneration observed in ALS. Especially, CD4+ T helper (Th) lymphocytes,
including Th2 lymphocytes and Treg, are found in the early neuroprotective compensatory response;
on the contrary, CD8+ T cytotoxic lymphocytes, such as Th1 and Th17 lymphocytes, are observed at
later stages of the disease [45,46]. Both types of T lymphocytes have shown a dual role: Th1 and Th17
expression was found elevated in blood from ALS patients [47], whereas an upregulation of Treg in
blood was associated with slower progression of the disease [48]. Similarly, increasing levels of Treg in
animal models at early stages in the disease prolonged survival [49].
Other cells involved in MN degeneration are monocytes and macrophages. They have been found
activated in peripheral blood and in CNS, especially in the spinal cord, due to the existent disruption
of the blood-spinal cord barrier, in both ALS patients and murine models [50,51]. In line with this,
some components of the complement system, which participate in the recruitment of mononuclear
cells and macrophages, have been found elevated in CSF, blood, spinal cord and skeletal muscle
from ALS patients or murine models [42,52,53]. However, the role of the complement system in ALS
pathogenesis remains controversial due to the diverging results based on the great inter-individual
differences during disease progression, although aberrant activation of the complement system is
suggested to be involved in the pathophysiology in ALS animal models and patients [52].
More recently, the relevant role of the mutation C9orf72 in myeloid cells opened the door to altered
microglial function that can link the connection between autoimmunity and ALS/FTD. Some studies on
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heterozygous C9orf72 (C9orf72+/–) mice have suggested an altered myeloid cell function and systemic
immunity. Accordingly, similar immunological consequences have been observed in ALS patients.
Therefore, the loss of function of C9orf72 together with a combination of mutations of ALS/FTD genes
could promote neurodegeneration [54]. Finally, the consequence of an altered microglia in both mutant
SOD1 mice and patients is an amplified generation of pro-inflammatory cytokines that can trigger
TNF-α-mediated apoptosis [55].
Despite the diverse humoral and cellular factors being found to be dysregulated, supporting the
evident role of neuroinflammation in ALS pathology, to date it is still unclear how these inflammatory
mediators can influence the progression of the disease and how they can be helpful in the diagnosis
of ALS.
4. Dysregulation of Cytokines in Biofluids
A high number of studies have been conducted to find dysregulated cytokines in CSF and blood
that can become potential biomarkers for ALS, mainly involving ALS patients, although few studies
have been also performed in ALS animal models.
4.1. Interleukins
Interleukins comprise of a large family of cytokines that can exert both pro-inflammatory and
anti-inflammatory actions. They are mainly synthesized by T cells, macrophages and endothelial cells
promoting the development and differentiation of T and B cells, and hematopoietic cells. Numerous
interleukins have been found elevated in CSF and/or blood from ALS patients compared to the levels
measured in controls and/or patients with other non-inflammatory neurological disorders (OND):
IL-1Ra, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-17A, IL-18
and IL-21 [26,47,56–70] (Table 1). Some of these interleukins follow the same pattern in the SOD1G93A
model. Increasing levels of IL-2, IL-6, IL-10, IL-13 and IL-17B R in the transgenic (TG) mice are observed
at an early stage of the disease [71]. In contrast, few studies reported decreasing levels of circulating
IL-2, IL-5, IL-6 and IL-10 in ALS patients [58,63,72], whereas others found no significant differences in
the levels of IL-2 and IL-6 in CSF or blood between ALS patients and their controls [73,74].
Table 1. Interleukins (IL) found dysregulated and proposed as biomarkers in biofluids from ALS
animal models and patients.
Cytokine Subject Biofluid Significance Reference
IL-1Ra Patients Blood Higher in ALS patients than in OND [61]
IL-1β Patients CSF, blood Higher in ALS patients than controls and/or OND [26,60,68]
IL-2
Mouse model Blood
Higher in TG mice than WT mice [71]
Negative correlation with longevity [71]
Patients
CSF, blood Higher in ALS patients than controls and/or OND [26,58,67,69,70]
Blood
Lower in ALS than healthy controls [63]
Predictor of poor survival [26]
IL-4 Patients
CSF, blood Higher in ALS patients than controls and/or OND [26,64]
CSF Higher levels associated with slower disease progression [64]
IL-5 Patients Blood
Higher in ALS patients than healthy controls [26]
Lower in ALS patients than healthy controls [63]
IL-6
Mouse model Blood
Higher in TG mice than WT mice [71]
Negative correlation with longevity [71]
Patients
CSF, blood Higher in ALS patients than controls and/or OND [26,47,58,63,65–68,70]
Blood Lower in ALS patients than controls [72]
Blood Rising levels associated with disease progression [26]
IL-7 Patients CSF Higher in ALS patients than in OND [60,64]
IL-8 Patients CSF, blood Higher in ALS patients than controls and/or OND [26,57,63,65,66,68,70]
IL-9 Patients CSF Higher in ALS patients than in OND [60]
Int. J. Mol. Sci. 2019, 20, 2759 5 of 17
Table 1. Cont.
Cytokine Subject Biofluid Significance Reference
IL-10
Mouse model Blood Higher in TG mice than WT mice [71]
Patients
Blood Higher in ALS patients than controls [26,67]
CSF, blood Lower in ALS patients than controls and/or OND [58,72]
CSF Higher levels associated with milder symptoms [64]
IL-12p70 Patients CSF, blood Higher in ALS patients than controls and/or OND [26,60]
IL-13
Mouse model Blood Higher in TG mice than WT mice [71]
Patients Blood
Higher in ALS patients than controls [26,56]
Negative correlation with ALSFRS-R score [56]
Positive correlation with the DPR [56]
IL-15 Patients CSF, blood Higher in ALS patients than controls and/or OND [58,67,69]
IL-17 Patients CSF, blood Higher in ALS patients than controls and/or OND [47,58,60,64,67,69]
IL-17A Patients Blood Higher in ALS than controls [59]
IL-17B R Mouse model Blood
Higher in TG mice than WT mice [71]
Higher levels associated with shorter survival [71]
IL-18 Patients Blood Higher in ALS patients than controls [62]
IL-21 Patients Blood Higher in ALS patients than controls [47]
Regarding the potential role of interleukins as prognostic biomarkers, rising levels of IL-4, IL-6
and IL-13 in CSF or blood from ALS patients were associated with disease progression and ALSFRS-R
score [26,56,64] (Table 1). Additionally, levels of IL-2 in plasma correlated with poorer survival in both
SOD1G93A mice and ALS patients [26,71]. In the animal model SOD1G93A, other interleukins found
in plasma, IL-6 and IL-17B R, have been related to faster or slower progression of the disease [71].
Despite the large number of interleukins that seems to participate in the interplay of
neuroinflammation in ALS pathogenesis, there is no definitive mediator that is being used in the
clinical setting to help in diagnosis or predicting progression.
4.2. Tumor Necrosis Factors
TNF-α is a major pro-inflammatory cytokine. It is primarily secreted by activated macrophages
and is involved in the induction of cytokine production, phagocyte cell activation, activation or
expression of adhesion molecules, and growth stimulation [75]. In regards to ALS, increased TNF-α
levels have been found in CSF and blood from ALS patients [26,60,65,68,69] (Table 2). On the contrary,
additional studies have shown lower levels TNF-α in blood from ALS patients [72]. Furthermore,
in some cases, TNF-α was not found altered in serum of ALS patients compared to controls [73] or its
levels in neither CSF nor blood did not correlate with the severity and progression of the disease [74].
Due to these controversial results, its function in ALS pathogenesis is still uncertain likely due to its
pleiotropic actions, as it can act in both pro- and anti-inflammatory responses [76].
Table 2. Tumor necrosis factors (TNF) found dysregulated and proposed as biomarkers in biofluids
from ALS animal models and patients.
Cytokine Subject Biofluid Significance Reference
TNF-α Patients
CSF, blood Higher in ALS patients than controls and/or OND [26,60,65,68,69]
Blood Lower in ALS patients than controls [72]
TNFRSF1 (CD120) Patients Blood Higher in ALS patients than controls [68,72]
TNFRSF8 L (CD30 L) Mouse model Blood Higher in TG mice than WT mice [71]
TNFRSF18 (GITR) Mouse model Blood
Lower in TG mice than WT mice [71]
Higher levels associated with shorter survival [71]
TNFRSF19 (TROY) Mouse model Blood
Higher in TG mice than WT mice [71]
Negative correlation with longevity [71]
TNFSF11 (RANKL) Mouse model Blood Higher in TG mice than WT mice [71]
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Although TNF-α is the most studied factor of this family, other TNFs have been found dysregulated
in ALS. For instance, blood levels of TNF Receptor Superfamily Member (TNFRSF)1A (CD120) were
higher in ALS patients than controls [68,72] (Table 2). In the same line, other TNFs, including TNFRSF8
L, TNFRSF19 and TNF Superfamily Member (TNFSF)11, were elevated, and TNFRSF18 was reduced
in the murine model SOD1G93A compared to the levels of WT mice at early stages of the disease [71].
In addition, the prognostic value of some of these factors has been evaluated, resulting in the association
of high levels of TNFRSF18 and TNFRSF19 with poorer survival [71].
4.3. Interferons (IFN)
The only circulating IFN found dysregulated in ALS patients to date is IFN-γ. This cytokine takes
part in both innate and adaptive immunity by participating in the activation of macrophages and in
the adaptive T cell response [28]. In ALS patients, IFN-γ has been found elevated in both CSF and
blood compared to the levels measured in controls and OND, and have been associated with faster
progression and shorter survival [47,60,67,77] (Table 3). In contrast, other studies suggested lower
levels of this factor in CSF and blood from ALS patients [26,58], which questions its role as a potential
biomarker for ALS.
Table 3. Interferons (IFN) found dysregulated and proposed as biomarkers in biofluids from
ALS patients.
Cytokine Subject Biofluid Significance Reference
IFN-γ Patients
CSF, blood
Higher in ALS than controls and/or OND patients [47,60,67,77]
Lower in ALS than controls or OND patients [26,58]
Positive correlation with DPR [67,77]
CSF Higher levels associated with shorter overall survival. [67]
4.4. Colony Stimulating Factors (CSFs)
CSFs are responsible for stimulating proliferation and maturation of myeloid precursors.
In particular, two of them have been linked to ALS: granulocyte (G)-CSF, involved in granulocyte
production, and granulocyte-macrophage (GM)-CSF, participating in granulocyte, monocyte and
eosinophil production. Both have been found increased in ALS patients in CSF and blood [58,60,64,67,69]
(Table 4). In addition, levels of GM-CSF in blood negatively correlated with the duration of symptoms,
which could help in the prognosis of the disease [78]. However, another study reported no significant
differences in G-CSF levels in serum between ALS patients and controls or other neuropathies [73].
Table 4. Colony stimulating factors (CSFs) found dysregulated and proposed as biomarkers in biofluids
from ALS patients.
Cytokine Subject Biofluid Significance Reference
G-CSF Patients CSF, blood Higher in ALS patients than controls and/or OND [58,60,64,67,69]
GM-CSF Patients
CSF, blood Higher in ALS patients than controls and/or OND [58,67]
Blood Negative correlation with duration of symptoms [78]
4.5. Chemokines
The main function of pro-inflammatory chemokines is to direct immune cells to the site of
inflammation via chemotaxis. As interleukins, this family encloses a vast group of both chemokines
and chemokine receptors. Regarding ALS, increased expression of several members of chemokines
was found in CSF or blood from ALS patients than in controls or OND: C–C motif chemokine ligand
(CCL)2, CCL3, CCL4, CCL11, C-X-C motif chemokine ligand (CXCL)8 and CXCL10; in addition, their
levels also correlated with ALSFRS-R score or disease progression rate (DPR) [57,58,60,64,67,69,78–80]
(Table 5). In the case of CCL5, higher levels were also found in ALS patients in CSF [61], but not in
blood, where its levels, together with CXC5R, were lower than in controls [72].
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Table 5. Chemokines found dysregulated and proposed as biomarkers in biofluids from ALS animal
models and patients.
Cytokine Subject Biofluid Significance Reference
CCL2 (MCP-1) Patients
CSF, blood
Higher in ALS patients than controls and/or OND [57,58,60,67,69,78,80]
Negative correlation with ALSFRS-R score [60,67]
Positive correlation with DPR [67]
Blood Negative correlation with duration of symptoms [78]
CCL3 (MIP-1α)
Mouse model Blood
Higher in TG mice than WT mice [71]
Negative correlation with longevity [71]
Patients CSF, blood
Higher in ALS patients than controls and/or OND [58,67,69,79]
Positive correlation with disease duration and
negative correlation with DPR
[67,79]
CCL4 (MIP-1β) Patients CSF
Higher in ALS patients than controls and OND [58,60,67,80]
Positive correlation with ALSFRS-R and disease
duration, and negative correlations with DPR
[60]
CCL5 (RANTES) Patients
CSF Higher in ALS patients than in OND [60]
Blood Lower in ALS patients than controls [72]
CCL11 (Eotaxin-1)
Mouse model Blood
Higher in TG mice than WT mice [71]
Higher levels associated with shorter survival and
negative correlation with longevity
[71]
Patients
CSF, blood Higher in ALS patients than in OND [57,60,64]
CSF Higher levels with slower DPR [64]
CCL19 (MIP-3β) Mouse model Blood Higher in TG mice than WT mice [71]
CCL21 (6Ckine) Mouse model Blood Higher in TG mice than WT mice [71]
CXC5R Patients Blood Lower in ALS patients than controls [72]
CXCL8 Patients CSF
Higher in ALS patients than in OND [60]
Negative correlation with ALSFRS-R score [60]
CXCL10 Patients CSF
Higher in ALS patients than in OND [60]
Negative correlation with DPR [60]
Similarly in the SOD1G93A model, four chemokines were upregulated at early stages in TG mice,
CCL3, CCL11, CCL19 and CCL21, suggesting a dysregulation of these mediators before the onset of
symptoms [71] (Table 5). In addition, CCL3 and CCL11 negatively correlated with the longevity of
TG mice.
4.6. Other Cytokines and Proteins Related to Inflammation
Other proteins related to inflammation have been linked to ALS pathogenesis showing modified
levels between ALS patients and their controls, and during disease progression (Table 6). Basic fibroblast
growth factor (bFGF) and platelet-derived growth factor (PDGF)-BB were found elevated in CSF or
blood in ALS patients [58,64,67]. On the contrary, other studies reported an association of high levels
of bFGF with slower progression of the disease, which could be contradictory [67].
In the case of vascular endothelial growth factor (VEGF), higher levels were described in blood and
CSF from ALS patients than in controls, whereas positive correlation with ALSFRS-R score and disease
duration was reported, supporting the potential role of VEGF for ALS prognosis [58,60,67–69,81].
Low levels were also found in CSF from ALS patients during the first year of the disease [82]. In addition,
an analysis combining VEGF with pNFH suggested a higher diagnostic yield [83].
Another cytokine altered in ALS is transforming growth factor beta (TGF-β), which is enrolled in
the inhibition of T and B cell proliferation, hematopoiesis, and promotion of wound healing. In this
case, higher levels were associated with faster progression of the disease in an ALS mouse model [84].
However, no differences were found in TGF-β levels in plasma from ALS patients [72].
Other proteins have also been shown to be altered in the SOD1G93A mouse model: activin
receptor-like kinase (ALK)-1, galectin-1 and VEGF-D were elevated in plasma of TG mice [71].
In addition, rising levels of ALK-1 and galectin-1 in TG mice were associated with shorter survival [71].
In contrast, lower levels of galectin-3 in plasma were found in fast-progressing TG mice [84].
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Interestingly, immunoglobulin G (IgG) antibodies have shown a relevant role for ALS prognosis.
For instance, it has been reported that frequency and quantity of an IgG glycan is dependent on the
ALS clinical stage in ALS animal models [85]. On the other hand, an increase in CSF IgG of the level of
galactosylated structures was reported in ALS patients, showing a potential predictive value in the
ROC analysis [86].
Table 6. Other cytokines and proteins related to inflammation found dysregulated and proposed as
biomarkers in biofluids from ALS animal models and patients.
Protein Subject Biofluid Significance Reference
ALK-1 Mouse model Blood
Higher in TG mice than WT mice [71]
Higher levels associated with shorter survival [71]
bFGF Patients
CSF, blood Higher in ALS patients than controls and/or OND [58,64,67]Positive correlation with disease duration [67]
Blood Negative correlation with DPR [67]
Galectin-1 Mouse model Blood
Higher in TG mice than WT mice [71]
Higher levels associated with shorter survival and negative
correlation with longevity
[71]
Galectin-3 Mouse model Blood Lower in fast-progressing TG mice at pre-symptomatic and
symptomatic than in WT mice
[84]
IgG Patients CSF Increased level of galactosylated structures [86]
PDGF-BB Patients CSF Higher in ALS patients than in OND [64]
TGF-β Mouse model Blood Higher in slow-progressing TG mice and lower in
fast-progressing TG mice at pre-symptomatic and symptomatic
than in WT mice
[84]
VEGF Patients
CSF Low levels at early stages of ALS [82]
CSF, blood
Higher in ALS patients than controls and/or OND [58,60,67–69]
Positive correlation with ALSFRS-R score and disease duration [60,67,81]
Negative correlation with DPR [81]
VEGF-D Mouse model Blood Higher in TG mice than WT mice [71]
5. Cytokines as Biomarkers: Main Challenges
Over the last decades, many CSF and blood inflammatory cytokines have been found dysregulated
in ALS, supporting the relevant contribution of neuroinflammation in the pathogenic mechanisms
leading to motor neuron degeneration in ALS. However, the results shown are not always consistent in
all the studies performed, which hampers the translation of a single cytokine as a biomarker to the
clinical practice. As an example, it has been reported that the levels of certain cytokines in plasma from
ALS patients were highly variable between the first and the second visit to the clinic, and even they
did not show differences with healthy controls in some cases [63], exposing the great heterogeneity
of the disease. In an attempt to deal with this issue, some authors have proposed that it would be
more appropriate to identify panels of biomarkers, rather than focusing on a single target [87,88].
In this sense, panels of cytokines have been analyzed to help in a more accurate prediction of disease
progression [89,90]. However, some authors suggest that these promising multivariate models should
also include other clinical parameters, such as ALS type (sporadic or familial), disease stage, anatomical
onset of motor neuron impairment and even age and gender [26,91].
Another problem that appears in the searching of circulating cytokines as biomarkers is the
influence exerted by the action of environment and other factors surrounding the patient. For instance,
the upregulation of some circulating cytokines, such as IL-6, IL-8, IL-10, G-CSF and TNF-α, has been
linked to exercise [92], and others, including IL-6 and TNF-α, are elevated in a hypoxia status [93],
which is a feature frequently found in ALS patients. In addition, the cytokine levels measured in
blood in healthy individuals are not stable markers [94]. Cytokines play a relevant role in the immune
system, and alterations in this system due to infections, injuries, tissue trauma or inflammation,
which is inherent in ALS, can unbalance the immune system, even more under neurodegenerative
conditions. This imbalance can promote an intra-individual variation that could explain the high
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variability of cytokine levels observed in ALS [40,94]. Furthermore, in the context of ALS and FTD, the
cytokine profile in blood is also challenging to interpret due to the disease state, environmental factors,
and genetic background of the individuals that can lead to controversial results [40].
Therefore, the consideration of circulating cytokines and other circulating targets as biomarkers
is being increasingly questioned, mainly due to the opposing and irreproducible results that have
been shown in different studies [95]. Additionally, the underlying causes, such as lack of sensitivity,
unsuitable normalization or variations in sample handling, together with the difficulties in cytokine
assays that are not performed in routine clinical methodology, establish this issue as a real challenge.
In an attempt to address this problem, Otto et al. proposed a roadmap for biomarker discovery and
provided standard operating procedures that could allow multicenter collaboration and validation of
the neurochemical markers discovered in ALS to facilitate their translation to the clinic [96]. In this
line, multicenter studies can also shed light on this controversial issue by confirming the results among
different centers in the world, as demonstrated in several multicenter studies performed with ALS
patients [97–99]. Accordingly, it could be interesting to contemplate multicenter studies regarding the
most promising inflammatory mediators, which could be helpful to validate them.
6. Design of Therapeutic Approaches Targeting Inflammation
Given the number of cytokines found dysregulated in ALS, in the last decades many studies
have translated the focus in assessing the potential role of those cytokines in therapies counteracting
inflammation in ALS. In fact, there are currently several clinical trials involving therapies targeting
neuroinflammation in ALS [42]. G-CSF is one of the targets that have provided beneficial results
when administrated in both animal models and patients [100–102]. Similarly, other studies have
shown that the administration of IL-33 or IFN-γ antibody delayed the disease onset and the motor
decline, respectively, in an ALS mouse model [103,104]. However, there are also controversial results
when translating the findings obtained in the animal model to ALS patients. For example, therapies
using thalidomide and lenalidomide to inactivate TNF-α prolonged lifespan and enhanced the motor
performance in the animal model [105,106]; in contrast, thalidomide treatment did not cause any
improvement when administrated to ALS patients [107]. Regarding IL-6, transgenic mice deficient in
IL-6 did not show any improvement, as well as a blocking IL-6 therapy in an ALS mouse model [108,109].
In view of this, it seems evident that therapies targeting a single factor could not provide meaningful
benefits in ALS patients, as well as in the search for a reliable biomarker. Hooten et al. address
questions on why these kinds of therapies are failing, highlighting that it could be too late when they
are applied, or that therapies might not hit appropriate targets [45].
Recently, cell-based therapies are emerging as a promising strategy to modulate the immune
system in ALS as they can influence different key immune targets. For instance, experimental treatments
based on mesenchymal stem cells (MSCs) have shown to raise concentrations of neurotrophic factors,
and elevate anti-inflammatory cytokines, which reduces neuroinflammation [43,110]. On the other
hand, therapies targeting Treg, which were associated with disease progression [27,111], have also
shown interesting results in ALS patients [112].
7. Conclusions
ALS is a multifactorial disease where different pathological mechanisms direct or indirectly
contribute to the degeneration of motor neurons. Neuroinflammation is one of these mechanisms
investigated, since the involvement of many inflammatory mediators in this disease has been widely
reported. However, the identification of specific cytokines to help in the diagnosis and also to
predict the progression of the disease in ALS patients is challenging due to the great heterogeneity
found in this disease. In addition, cytokines are variable and susceptible to the disease stage
and to environmental factors surrounding ALS patients, who do not show an equal status of
neuroinflammation. Consequently, the different pro and anti- inflammatory cytokines along the
disease progression should be further studied to understand its time point activation and its relation to
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other molecular and clinical mediators in ALS to finally provide a better monitorization of disease
progression. In this sense, cytokines could be helpful in improving the stratification of ALS patients
according to their inflammatory status, enabling more accurate therapeutic approaches targeting these
key immune factors.
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ALK-1 Activin receptor-like kinase 1
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CSF Cerebrospinal fluid
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